Bristol-Myers Squibb to acquire Celgene in deal worth $74 billion
Posted on07 Jan 2019
Comments0
BMS - Celgene acquisition deal
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
Posted on18 Dec 2018
TagsBioverati, global pharma deals, global pharma licensing deal, pharma acquisition, pharma deal, Sanofi
Comments0
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive... Read More
2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
Posted on18 Dec 2018
TagsAveXis, global pharma deals, global pharma licensing deal, novartis, pharma acquisition, pharma deal
Comments0
Novartis has agreed to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per share or a total of... Read More
Consequences and progress of Takeda-Shire Buyout
Takeda announced in April it would buy Shire in the largest-ever overseas acquisition by a Japanese company. Although Shire is based in... Read More
Insight on Novo Nordisk’s acquisition of Bristol, UK-based Ziylo for $800 million
Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator... Read More
Big Pharma Acquisition: Takeda to acquire Shire for $62 billion
Takeda Pharmaceutical Co. of Japan has finalized an agreement to buy Shire PLC, the second-biggest biotech employer in Massachusetts, for $62 billion... Read More
Case Study: GSK to acquire Novartis’s consumer healthcare stake for $13bn
Posted on28 Mar 2018
Tagsacquisition in pharma, brand acquisition, GSK, novartis, OTC drugs, otc monograph, pharma acquisition
Comments0
Swiss drugmaker, Novartis agreed to sell GSK its stake in their consumer health joint venture for $13bn. GlaxoSmithKline will be getting the... Read More
Case Study: Sanofi’s acquisition of Ablynx for $4.8 bn
French drugmaker Sanofi has agreed to acquire Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion). This is second deal of... Read More
Novatis’ LUTATHERA® Approval: First FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)
Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that it has received US Food and... Read More
Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2 billion
Mallinckrodt plc, a leading global specialty pharmaceutical company, and Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, have entered into an agreement under... Read More